Communique of GTTAC meeting of 20 July 2020
This Communiqué covers matters considered at the 20th video conference of the Gene Technology Technical Advisory Committee (20 July 2020).
Licence application DIR 174 from Biocelect Pty Ltd is for the import, transport, storage and disposal of a genetically modified (GM) cholera vaccine, Vaxchora®, as part of its commercial supply in Australia.
The Committee discussed the issues identified for consideration in the consultation RARMP being prepared by the Regulator, including possible pathways to environmental exposure and the potential for the GMO to persist in the environment. In addition, GTTAC raised the possibility of the GMO acquiring other genes via gene transfer leading to multidrug resistant bacteria, and the potential for these to form biofilms. GTTAC indicated the probability of this occurring is low, however recommended it be considered in the RARMP.